Literature DB >> 23609520

Changes of cytokine profiles during electroconvulsive therapy in patients with major depression.

Andrea Rotter1, Teresa Biermann, Christiane Stark, Anja Decker, Joachim Demling, Rüdiger Zimmermann, Wolfgang Sperling, Johannes Kornhuber, Andreas Henkel.   

Abstract

OBJECTIVES: Electroconvulsive therapy (ECT) is an effective treatment of depression, but its mechanism of action still remains unknown. Some studies emphasize that epileptic seizures result in cerebral production of cytokines, including the cytokine network in association with the pathophysiology of depression. We hypothesized that depressed patients would show a dysregulated profile of peripheral cytokines before and after ECT treatment.
METHODS: Fifteen hospitalized subjects with major depressive disorder were recruited. Human cytokine array IV was used to determine the profile of cytokines in the serum during the course of ECT. Positive results of the cytokine assay were verified by reverse transcriptase-polymerase chain reaction. Depressive symptoms were evaluated before and after ECT series.
RESULTS: The signal intensity of eotaxin-3 and interleukin (IL)-5 changed statistically significantly between the first ECT and 24 hours after the last ECT. Furthermore, there were significant correlations between the signal intensities of eotaxin-3, bone morphogenetic protein 6, IL-5, and transforming growth factor-β and the severity of depression. The results of Cytoray assays were confirmed partly by reverse transcriptase-polymerase chain reaction. The changes of tumor necrosis factor β in pre-post comparison of ECT and the correlation of the Montgomery-Asberg Depression Scale score with tumor necrosis factor β, IL-5, and bone morphogenetic protein 6 expression could be verified. Only the relative signal intensity of IL-16 correlated significantly with the clinically as well as electroencephalographically measurable seizure duration.
CONCLUSION: Electroconvulsive therapy treatment seems to change the expression of various cytokines in relation to changes of affective states such as mood. Therefore, cytokines might play a specific role within the treatment and pathogenesis of affective disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609520     DOI: 10.1097/YCT.0b013e3182843942

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  13 in total

Review 1.  Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy.

Authors:  Jiangling Jiang; Jijun Wang; Chunbo Li
Journal:  Neurosci Bull       Date:  2016-12-28       Impact factor: 5.203

2.  Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy.

Authors:  Gavin Rush; Aoife O'Donovan; Laura Nagle; Catherine Conway; AnnMaria McCrohan; Cliona O'Farrelly; James V Lucey; Kevin M Malone
Journal:  J Affect Disord       Date:  2016-06-17       Impact factor: 4.839

3.  Inflammation and depression treatment response to electroconvulsive therapy: Sex-specific role of interleukin-8.

Authors:  Jennifer L Kruse; Richard Olmstead; Gerhard Hellemann; Benjamin Wade; Janina Jiang; Megha M Vasavada; John O Brooks Iii; Eliza Congdon; Randall Espinoza; Katherine L Narr; Michael R Irwin
Journal:  Brain Behav Immun       Date:  2020-05-29       Impact factor: 19.227

4.  Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders.

Authors:  Chiyo Shibasaki; Minoru Takebayashi; Kei Itagaki; Hiromi Abe; Naoto Kajitani; Mami Okada-Tsuchioka; Shigeto Yamawaki
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-31       Impact factor: 5.176

5.  Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia.

Authors:  Yong-Fang Guo; Hua-Bin Fu; Zhi-Yuan Liu; Wei Lu; Ke-Yong Luo; Hong-Ri Zhu; Wei-Dong Ning; Feng Chen; Li-Yu Yang; Xiao-Dong Zhou
Journal:  Exp Ther Med       Date:  2017-01-20       Impact factor: 2.447

6.  Low tumor necrosis factor-α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder.

Authors:  Annamari Sorri; Kaija Järventausta; Olli Kampman; Kai Lehtimäki; Minna Björkqvist; Kati Tuohimaa; Mari Hämäläinen; Eeva Moilanen; Esa Leinonen
Journal:  Brain Behav       Date:  2018-02-22       Impact factor: 2.708

7.  FoxO1, A2M, and TGF-β1: three novel genes predicting depression in gene X environment interactions are identified using cross-species and cross-tissues transcriptomic and miRNomic analyses.

Authors:  Annamaria Cattaneo; Nadia Cattane; Chiara Malpighi; Darina Czamara; Anna Suarez; Nicole Mariani; Eero Kajantie; Alessia Luoni; Johan G Eriksson; Jari Lahti; Valeria Mondelli; Paola Dazzan; Katri Räikkönen; Elisabeth B Binder; Marco A Riva; Carmine M Pariante
Journal:  Mol Psychiatry       Date:  2018-01-04       Impact factor: 15.992

Review 8.  Glia in the cytokine-mediated onset of depression: fine tuning the immune response.

Authors:  Wendy K Jo; Yuanyuan Zhang; Hinderk M Emrich; Detlef E Dietrich
Journal:  Front Cell Neurosci       Date:  2015-07-10       Impact factor: 5.505

9.  Leukocyte Gene Expression in Patients with Medication Refractory Depression before and after Treatment with ECT or Isoflurane Anesthesia: A Pilot Study.

Authors:  E Iacob; S C Tadler; K C Light; H R Weeks; K W Smith; A T White; R W Hughen; T A VanHaitsma; L A Bushnell; A R Light
Journal:  Depress Res Treat       Date:  2014-04-13

10.  Possible Association between Serum Matrix Metalloproteinase-9 (MMP-9) Levels and Relapse in Depressed Patients following Electroconvulsive Therapy (ECT).

Authors:  Chiyo Shibasaki; Kei Itagaki; Hiromi Abe; Naoto Kajitani; Mami Okada-Tsuchioka; Minoru Takebayashi
Journal:  Int J Neuropsychopharmacol       Date:  2018-03-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.